Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

114
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
114
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

12
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
12
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

7
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
7
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

6
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
6
Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

886
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
886
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

8
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
8

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of glucagon-like peptide-1 receptor agonists on psychiatric disorders: a systematic review.

Therapeutic advances in psychopharmacology·2025
Same author

Ritual to relief: ethical frontiers in repurposing psychoactive substances.

CNS spectrums·2025
Same author

MAOI Antidepressants: A History Being Rewritten.

The Journal of clinical psychiatry·2025
Same author

Toward Precision Psychiatry: Innovations and Prospects in Treating Depression.

The primary care companion for CNS disorders·2025
Same author

Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder: Results From a Randomized, Double-Blind, Phase 3 Trial.

The Journal of clinical psychiatry·2025
Same author

Reply to Letter From Surekha et al: "Lumateperone for Mixed Features in MDD and Bipolar Depression: Advancing Treatment or Raising New Questions".

Journal of clinical psychopharmacology·2025
Same journal

Computational Study of ADME-TOx from Selected Phytocompounds of Solanum tuberosum and Cucumis sativus.

Current medicinal chemistry·2026
Same journal

QSAR-Based Strategies for Selective-HDAC6 Inhibitor Development: A Detailed Review.

Current medicinal chemistry·2026
Same journal

Breaking New Ground in Oncology: FDA Acceptance of Vepdegestrant NDA Marks a Milestone for PROTAC Therapies in Breast Cancer.

Current medicinal chemistry·2026
Same journal

Knockdown of circFGFR2 inhibits prostate cancer cell metastasis and proliferation by targeting miR-221-5p/ SMUG1 pathway.....

Current medicinal chemistry·2026
Same journal

LncRNA signature associated with amino acid metabolism: A novel prognostic tool for Clear Cell Renal Cell Carcinoma.

Current medicinal chemistry·2026
Same journal

HRI Kinase Modulation by BTdCPU as a Therapeutic Strategy for Bortezomib Resistance in Prostate Cancer.

Current medicinal chemistry·2026
See all related articles

Related Experiment Video

Updated: Oct 7, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.9K

Polypharmacy- Purpose, Benefits and Limitations.

Douglas Grover1, Michelle Tom1, Gerald Maguire1

  • 1Department of Psychiatry, University of California, Riverside, California 92521, USA.

Current Medicinal Chemistry
|January 7, 2022
PubMed
Summary
This summary is machine-generated.

Polypharmacy, the use of multiple medications, is common in psychiatry due to comorbid conditions. When used judiciously, it can significantly improve patient outcomes despite its negative connotations.

Keywords:
GABAPolypharmacyangiotensin-converting enzymeantidepressantneural circuitryneurotransmitters

More Related Videos

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.9K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

401

Related Experiment Videos

Last Updated: Oct 7, 2025

Diagonal Method to Measure Synergy Among Any Number of Drugs
12:08

Diagonal Method to Measure Synergy Among Any Number of Drugs

Published on: June 21, 2018

18.9K
Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations
11:15

Quadruple-Checkerboard: A Modification of the Three-Dimensional Checkerboard for Studying Drug Combinations

Published on: July 24, 2021

4.9K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

401

Area of Science:

  • Psychiatry
  • Clinical Pharmacology

Background:

  • Increasing prevalence of comorbid psychiatric and mental health conditions presents challenges in medical specialties.
  • Physicians frequently encounter complex treatment decisions involving polypharmacy.

Purpose of the Study:

  • To address the challenges and perceptions surrounding polypharmacy in psychiatric care.
  • To highlight the potential benefits of polypharmacy when managed with clinical expertise.

Main Methods:

  • Review of clinical decision-making processes in managing patients with multiple comorbidities.
  • Pharmacological assessment of risks and benefits associated with polypharmacy.

Main Results:

  • Polypharmacy is a common, yet often negatively perceived, practice in managing complex psychiatric cases.
  • Judicious use of polypharmacy, guided by clinical judgment and pharmacological knowledge, can be beneficial.

Conclusions:

  • Despite negative connotations, polypharmacy can be a valuable therapeutic strategy in psychiatry.
  • Emphasizes the importance of risk-benefit analysis and expert application in polypharmacy for improved patient outcomes.